Low-density lipoprotein (LDL) apheresis reduces atherogenic and oxidative markers in uremic patients with hyperlipidemia.
Uremic patients with hyperlipidemia are classified at high atherogenic risk due to oxidative stress induced by regular hemodialysis process (hemoincompatibility) and a high level of oxidized low-density lipoprotein (ox-LDL). This study aimed to investigate whether LDL apheresis was capable of reducing oxidative and atherogenic markers in uremic patients with hyperlipidemia. We found that oxidative metabolites (methylquanidine, dityrosine, and ox-LDL) and atherogenic markers (lipoprotein (a), LDL, and LDL/HDL ratio) were significantly reduced (P < 0.05) after LDL apheresis. On the other hand, plasma total antioxidant status (TAS) was not influenced after LDL apheresis. Our results suggest that LDL apheresis reduces oxidative and atherogenic markers and do not influence plasma TAS in uremic patients with hyperlipidemia. This may lead to a decreased risk of atherosclerosis in these patients. However, supplementation of dietary proteins may be necessary because of the removal of some "useful" proteins (e.g., albumin and globulin) after LDL apheresis.
Chen
Tung-Sheng
TS
Graduate Institute of Basic Medical Science, China Medical University, Taichung, 404, Taiwan.
Liou
Show-Yih
SY
Wu
Hsi-Chin
HC
Tsai
Fuu-Jen
FJ
Tsai
Chang-Hai
CH
Huang
Chih-Yang
CY
Chang
Yen-Lin
YL
D050197:Atherosclerosis / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D001781:Blood Component Removal; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D008077:Lipoproteins, LDL; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D014511:Uremia / Q000150:complications / Q000378:metabolism / Q000628:therapy*
D008077:Lipoproteins, LDL